Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Cultivates Early Stage Science Through A Trio Of Initiatives

This article was originally published in The Pink Sheet Daily

Executive Summary

The pharma opened its California Innovation Center in Menlo Park, announced a planned expansion of its incubator to San Francisco and started a program to help entrepreneurs start new life science companies.

You may also be interested in...



California Dreaming: J&J Builds Bay Area Ties With Second Startup Home

Among other startups selected by J&J, remote-controlled CAR therapy company Driver BioEngineering and neurodegenerative disease specialist Alkahest have secured a home in new South San Francisco incubator, where they can tap into expertise and equipment with “no strings attached.”

J&J’s New Innovation Centers Test Immersion Theory Of Access

Johnson & Johnson executives including Pharma Chairman and CSO Paul Stoffels explain how building a presence in innovation’s backyard will allow the health care giant to more easily and quickly access new assets and technologies. Can proximity to innovation make J&J more innovative?

Backing New Index Fund, GSK, J&J Buy Into Asset-Centric Vision Of Biotech Future

Index Life VI is the first life-sciences-only fund for Index; GSK’s Moncef Slaoui and J&J’s Paul Stoffels are on scientific advisory board.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS075927

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel